• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[Venetoclax combined with hypomethylating agents induced tumor lysis syndrome in patients with acute leukemia: 7 cases report and literature review].

作者信息

Guo Y S, Zhao C H, Hu D Y, Shen K, Chen S N

机构信息

Department of Hematology, the First Affiliated Hospital of Soochow University, Suzhou 215006, China.

Department of Clinical Laboratory, the Second Affiliated Hospital of Soochow University, Suzhou 215004, China.

出版信息

Zhonghua Xue Ye Xue Za Zhi. 2023 Jun 14;44(6):508-511. doi: 10.3760/cma.j.issn.0253-2727.2023.06.013.

DOI:10.3760/cma.j.issn.0253-2727.2023.06.013
PMID:37550210
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10450560/
Abstract
摘要

相似文献

1
[Venetoclax combined with hypomethylating agents induced tumor lysis syndrome in patients with acute leukemia: 7 cases report and literature review].[维奈克拉联合低甲基化药物诱导急性白血病患者发生肿瘤溶解综合征：7例报告及文献复习]
Zhonghua Xue Ye Xue Za Zhi. 2023 Jun 14;44(6):508-511. doi: 10.3760/cma.j.issn.0253-2727.2023.06.013.
2
Tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax and hypomethylating agents with or without dose ramp-up.伴有或不伴有剂量爬坡的 venetoclax 和低甲基化剂治疗的急性髓系白血病患者的肿瘤溶解综合征。
Leuk Lymphoma. 2024 Feb;65(2):228-234. doi: 10.1080/10428194.2023.2276056. Epub 2024 Jan 24.
3
Venetoclax plus hypomethylating agents or low-dose cytarabine in acute myeloid leukemia: all that glitters is gold?维奈托克联合去甲基化药物或小剂量阿糖胞苷治疗急性髓系白血病：闪光的都是金子吗？
Blood Cancer J. 2020 Jan 28;10(1):10. doi: 10.1038/s41408-020-0281-x.
4
Tumor lysis syndrome risk in outpatient versus inpatient administration of venetoclax and hypomethlators for acute myeloid leukemia.门诊与住院患者接受 venetoclax 和低甲基化药物治疗急性髓系白血病的肿瘤溶解综合征风险。
Support Care Cancer. 2021 Sep;29(9):5323-5327. doi: 10.1007/s00520-021-06119-7. Epub 2021 Mar 4.
5
How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia.我们如何将维奈托克与低甲基化剂联合用于治疗新诊断的急性髓系白血病患者。
Leukemia. 2019 Dec;33(12):2795-2804. doi: 10.1038/s41375-019-0612-8. Epub 2019 Oct 18.
6
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).比较维奈托克联合低甲基化药物与低甲基化药物为基础的治疗方案用于初治 TP53 突变急性髓系白血病：来自髓系恶性肿瘤和肿瘤性疾病联盟（COMMAND）的结果。
Blood Cancer J. 2024 Feb 20;14(1):32. doi: 10.1038/s41408-024-01000-2.
7
Is venetoclax the new backbone of acute myeloid leukaemia therapy?维奈克拉会成为急性髓系白血病治疗的新支柱吗？
Lancet Haematol. 2021 Aug;8(8):e536-e537. doi: 10.1016/S2352-3026(21)00205-2.
8
Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study.维奈克拉治疗对低甲基化剂耐药的急性髓系白血病患者：一项多中心历史前瞻性研究。
Ann Hematol. 2019 Aug;98(8):1927-1932. doi: 10.1007/s00277-019-03719-6. Epub 2019 Jun 11.
9
Risk of tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax-containing regimens without dose ramp-up.在接受不含剂量递增的含维奈克拉方案治疗的急性髓系白血病患者中发生肿瘤溶解综合征的风险。
Ann Hematol. 2021 Feb;100(2):595-599. doi: 10.1007/s00277-020-04181-5. Epub 2020 Jul 23.
10
Outcomes of allogeneic transplantation after hypomethylating agents with venetoclax in acute myeloid leukemia.急性髓系白血病中使用去甲基化药物联合维奈克拉进行异基因移植的结果。
Am J Hematol. 2022 Jun 1;97(6):E191-E194. doi: 10.1002/ajh.26524. Epub 2022 Mar 18.

本文引用的文献

1
Venetoclax with Azacitidine Induced Tumor Lysis Syndrome in an Elderly Patient with Acute Myeloid Leukemia: A Case Report.维奈克拉联合阿扎胞苷致老年急性髓系白血病患者肿瘤溶解综合征：一例报告
Electrolyte Blood Press. 2021 Dec;19(2):46-50. doi: 10.5049/EBP.2021.19.2.46. Epub 2021 Dec 23.
2
Real-world treatment sequencing and healthcare costs among CLL/SLL patients treated with venetoclax.真实世界中接受 venetoclax 治疗的 CLL/SLL 患者的治疗序贯和医疗保健成本。
Curr Med Res Opin. 2021 Aug;37(8):1409-1420. doi: 10.1080/03007995.2021.1929894. Epub 2021 Jun 7.
3
Venetoclax-containing regimens in acute myeloid leukemia.急性髓系白血病中含维奈克拉的治疗方案。
Ther Adv Hematol. 2021 Feb 11;12:2040620720986646. doi: 10.1177/2040620720986646. eCollection 2021.
4
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.阿扎胞苷和维奈托克治疗未经治急性髓系白血病。
N Engl J Med. 2020 Aug 13;383(7):617-629. doi: 10.1056/NEJMoa2012971.
5
Risk of tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax-containing regimens without dose ramp-up.在接受不含剂量递增的含维奈克拉方案治疗的急性髓系白血病患者中发生肿瘤溶解综合征的风险。
Ann Hematol. 2021 Feb;100(2):595-599. doi: 10.1007/s00277-020-04181-5. Epub 2020 Jul 23.
6
How I treat acute myeloid leukemia in the era of new drugs.如何在新药时代治疗急性髓系白血病。
Blood. 2020 Jan 9;135(2):85-96. doi: 10.1182/blood.2019001239.
7
Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus.恶性肿瘤成人和儿童肿瘤溶解综合征（TLS）风险评估和预防推荐：专家 TLS 小组共识。
Br J Haematol. 2010 May;149(4):578-86. doi: 10.1111/j.1365-2141.2010.08143.x. Epub 2010 Mar 16.
8
An integrated clinical approach for the identification, prevention, and treatment of tumor lysis syndrome.肿瘤溶解综合征的识别、预防和治疗的综合临床方法。
Cancer Treat Rev. 2010 Apr;36(2):164-76. doi: 10.1016/j.ctrv.2009.11.001. Epub 2009 Dec 23.